Bronchitis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Bronchitis – Drugs In Development, 2024 report and make more profitable business decisions.
Bronchitis is an inflammation of the lining of bronchial tubes, which carry air to and from lungs. Symptoms include cough that produces mucus (sputum), which may be blood streaked; shortness of breath aggravated by exertion or mild activity; frequent respiratory infections worsen symptoms; wheezing, fatigue, and headaches. Risk factors include smoking, older age and gastric reflux.
The Bronchitis drugs in development market research report provide comprehensive information on the therapeutics under development for Bronchitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bronchitis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Bronchitis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 28 molecules, with 28 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Bronchitis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Bronchitis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Bronchitis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Adare Pharma SolutionsAstraZeneca Plc
Beijing Tri-Prime Genetic Engineering Co Ltd
Boehringer Ingelheim International GmbH
Chiesi Farmaceutici SpA
Daewon Pharmaceutical Co Ltd
Enzyvant Sciences Ltd
F. Hoffmann-La Roche Ltd
FUJIFILM Toyama Chemical Co Ltd
Hunan Sanqing Pharmaceutical Co Ltd
Icure Pharmaceutical Inc
Incannex Healthcare Ltd
Kexing Biopharm Co Ltd
Koutif Therapeutics LLC
Mereo Biopharma Group Plc
Novartis AG
NuPeak Therapeutics Inc
OrphAI Therapeutics Inc
PharmaLundensis AB
Regeneron Pharmaceuticals Inc
Renovion Inc
RS BioTherapeutics Inc
SolAeroMed Inc
Theron Pharmaceuticals Inc
Trove Therapeutics Inc
Verra Therapeutics LLC
Zambon Co SpA
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Bronchitis reports